

List of Tables

Sr. No:	Table No.	Table title	Page No.
1	2.1	Potential MMP inhibitors	34
2	4.1	Socio-demographic details of the subjects	45
3	4.2	Clinical details of oral cancer patients	46
4	4.3	Methodologies employed for analysis of parameters	48
5	4.4	Primer sequence and amplicon size of genes	65
6	4.5	Reaction conditions for RT-PCR analysis	66
7	5.1	Significance of expression levels of 192 kDa, 170 kDa, 116 kDa and 44 kDa glycoprotein in TNH and TH Controls with TNH and TH oral cancer patients	78
8	5.2	Comparison of serum and salivary TSA/TP ratio between TNH and TH groups of subjects	84
9	5.3	Comparison of serum and salivary TSA/TP ratio according to stage of the disease and metastasis	86
10	5.4	ROC curve analysis for serum and salivary TSA/TP ratio	87
11	5.5	Survival analysis of serum and salivary TSA/TP ratio	88
12	5.6	Serum and salivary sialidase activity in metastasis and various stages of disease	90
13	5.7	ROC curve analysis for serum and salivary sialidase activity	91
14	5.8	Kaplan Meir's survival analysis of serum and salivary sialidase activities with ROC cut-off	92
15	5.9	Serum and salivary α -2,3 and α -2,6 sialoproteins in various stages and metastasis	95
16	5.10	ROC curve analysis for serum and salivary α -2,3 and α -2,6 sialoproteins	97
17	5.11	Serum and salivary α -2,3 and α -2,6 ST activities with clinico-pathological parameters	100
18	5.12	ROC curve analysis for serum and salivary α -2,3 ST and α -2,6 ST	100
19	5.13	Significance of serum and salivary α -2,3 and α -2,6 ST in distinguishing PT vs. CR and PT vs. NR	101
20	5.14	Survival analysis of serum and salivary α -2,3 and α -2,6 ST with ROC cut-off	102
21	5.15	Pearson's correlation analysis between serum sialylation changes	103
22	5.16	Pearson's correlation analysis between salivary sialylation changes	103
23	5.17	ROC curve analysis for serum and salivary fucoproteins	107
24	5.18	Serum and salivary α -L-fucosidase activity in TNH and TH subgroups	109
25	5.19	Comparison of Serum and salivary α -L-fucosidase activity according to stage and metastasis	110
26	5.20	ROC curve analysis for serum and salivary α -L-fucosidase activity	111

27	5.21	Survival analysis of serum and salivary α -L-fucosidase activity with ROC cut-off	112
28	5.22	ROC curve analysis of the transcripts showing cut-off, sensitivity, specificity, and AUC	117
29	5.23	Multivariate analysis of <i>ST3GAL1</i> , <i>FUT3</i> , <i>FUT5</i> and <i>FUT6</i> transcripts with clinico-pathological parameters	120
30	5.24	Comparison of pro, active and total MMP-2 and MMP-9 in controls, patients with OPC and oral cancer patients. p values by student's 't' test	124
31	5.25	Correlation analysis between different forms of MMP-2 and MMP-9	124
32	5.26	Multivariate analysis of different forms of plasma MMP-2 and MMP-9 with various clinic-pathological parameters	126
33	5.27	ROC curve analysis of plasma pro, active and total MMP-2 and MMP-9	127
34	5.28	Survival analysis of different forms of plasma MMPs using ROC cut-off	128
35	5.29	Correlation analysis between all forms of salivary MMPs	131
36	5.30	ROC curve analysis of salivary pro MMP-9, active MMP-9 and truncated 42 kDa MMP	132
37	5.31	Survival analysis of different forms of salivary MMPs using ROC cut-off	132
38	5.32	Survival analysis of truncated E-cadherin protein and <i>ECAD</i> mRNA	135
39	5.33	<i>CJUN</i> mRNA expression with reference to stage and metastasis	137
40	5.34	Survival analysis of <i>CJUN</i> mRNA and protein with ROC cut-off	139
41	5.35	Pearson's correlation between plasma MMPs and serum glycosylation changes	144
42	5.36	Pearson's correlation between salivary MMPs and salivary glycosylation changes	145
43	5.37	Pearson's correlation between glycosylation, <i>ECAD</i> mRNA and protein, <i>CJUN</i> mRNA and protein	146
44	5.38	Pearson's correlation between E-cadherin protein and mRNA, <i>CJUN</i> mRNA and Protein	146
45	5.39	Correlation analysis of plasma and salivary MMPs with E-cadherin and c-Jun protein and mRNA	147
46	5.40	Correlation between pEGFR, truncated E-cadherin protein, plasma MMPs and c-Jun	148